The results in the previous section suggest activation of GRIN2A is a promising mechanism to pursue in developing novel antipsychotics, and since schizophrenia is a heterogeneous clinical condition, it is possible that activation of GRIN2A may be most promising for treating individuals with a specific clinical presentation. This evidence concerns the gene GRIN2A and schizophrenia.